A
Anne Boulay
Researcher at Novartis
Publications - 25
Citations - 2036
Anne Boulay is an academic researcher from Novartis. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Cancer. The author has an hindex of 13, co-authored 21 publications receiving 1980 citations. Previous affiliations of Anne Boulay include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation
Iwan Beuvink,Anne Boulay,Stefano Fumagalli,Frederic Zilbermann,Stephan Ruetz,Terence O'reilly,Francois Natt,Jonathan Hall,Heidi Lane,George Thomas +9 more
TL;DR: It is shown that RAD001 (everolimus), a rapamycin derivative, dramatically enhances cisplatin-induced apoptosis in wild-type p53, but not mutant p53 tumor cells, showing that a general effect on a major anabolic process may dramatically enhance the efficacy of an established drug protocol in the treatment of cancer patients with solid tumors.
Journal ArticleDOI
Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
Anne Boulay,Joëlle Rudloff,Jingjing Ye,Sabine Zumstein-Mecker,Terence O'reilly,Dean B. Evans,Shiuan Chen,Heidi Lane +7 more
TL;DR: In this paper, the role of the mTOR pathway in estrogen response was evaluated in aromatase-expressing MCF7/Aro breast cancer cells by immunoblotting.
Journal ArticleDOI
Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
Anne Boulay,Sabine Zumstein-Mecker,Christine Stephan,Iwan Beuvink,Frederic Zilbermann,Roland Haller,Sonja Tobler,Christoph Heusser,Terence O'reilly,Barbara Stolz,Andreas Marti,George Thomas,Heidi Lane +12 more
TL;DR: A correlation between the antitumor efficacy of intermittent RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs is demonstrated and suggest that long-term monitoring of PBMC-derived S 6K1 activity levels could be used for assessing RAD001treatment schedules in cancer patients.
Journal ArticleDOI
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Heidi Lane,Jeanette Marjorie Wood,Paul M.J. McSheehy,Peter R. Allegrini,Anne Boulay,Joseph Brueggen,Amanda Littlewood-Evans,Sauveur-Michel Maira,Georg Martiny-Baron,Christian Schnell,Patrizia Sini,Terence O'reilly +11 more
TL;DR: VEGFR and mTOR inhibitors show similar but also distinct effects on tumor vascular biology, which has implications for their clinical activity alone or in combination.
Journal ArticleDOI
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka,Terence O'reilly,John M. Kovarik,N. Shand,Katharine Hazell,Ian Judson,Eric Raymond,Sabine Zumstein-Mecker,Christine Stephan,Anne Boulay,Marc Hattenberger,George Thomas,Heidi Lane +12 more
TL;DR: A direct-link PK/PD model predicting the time course of S6K1 inhibition during weekly and dailyEverolimus administration allowed extrapolation from preclinical studies and first clinical results to select optimal doses and regimens of everolimus to explore in future clinical trials.